|
|
|
|
Recent Presentations
|
PP Presentation (1.25M) |
ERCC1 Expression in Non Non-Small Cell Lung
Cancer
NSCLC accounts for ~75% of all lung cancers
– Squamous cell carcinoma
– Adenocarcinoma
– Large cell undifferentiated carcinoma
• Most patients are considered for chemotherapy
at some time during the course of disease
• Current SOC – for above average risk patients
with locally advanced NSCLC, COMBINED platinum
platinum-based chemotherapy & radiation (after
complete resection) |
PP Presentation (268k) |
JAK2 V617F Mutation
Tyrosine kinase protein which is a member of
the Janus Family (a.k.a. JAK;”just another
kinase”)
•Attaches to cytoplasmic domain of cell surface
tyrosine kinase associated receptors.
•Serves as intermediary between cell surface and
nucleus via JAK-STAT pathway.
•The receptors bind several cytokines, growth
hormone, prolactin,and interferons alpha,beta
and gamma.
•Thus JAK2 is involved in cell growth,
signaling, regulation. |
PP Presentation (366k) |
Topoisomerase IIαstatus in Breast Cancer
Patients
It is valid to identify breast cancer
patients that show amplification of
Topoisomerase IIαand use this information to
tailor drug therapy. |
Dr. Nordberg s spoke
at the AACC (American Association of Clinical Chemistry)
Tuesday July 17, 2007.
The title
of her presentation was "Enhancing Workflow Efficiency in
Molecular testing using a Automated Multiplexing
Platform."
Contact the
lab for more detailed information.
Annual Meeting for the Association of Molecular
Pathology
The LSUHSC-S Department of Pathology had a strong
presence at the recent annual meeting for the
Association of Molecular Pathology (AMP) in Orlando,
Fla., with several residents and staff presenting
research projects. They included Amal Anga, M.D.,
third-year resident; Rodney Shackelford, D.O.,
fourth-year resident; Ami Bhalodia, M.D., third-year
resident; Brandi Painter, M.D., second-year resident;
and Sherry Martin, Clinical Associate. Mary Lowery
Nordberg, Ph.D., Associate Professor, served as faculty
mentor for all participants. The LSUHSC-S group
presented six posters. Also in attendance was Janice
Matthews-Greer, Ph.D., Assistant Professor, Department
of Pediatrics, Director of Virology Lab.
Dr. Nordberg, a founding member in the society, is
the Chair-Elect for the Genetics Subdivision of AMP and
currently serves on the program committee for the 2007
AMP meeting to be held in Los Angeles in November. AMP
is a not-for-profit scientific society dedicated to the
advancement, practice, and science of clinical molecular
laboratory medicine and translational research based on
the applications of genomics and proteomics.
Specialty: Hem/Onc Disease: CML
Full abstract: (Click
here)
Survival among chronic myelogenous leukemia (CML)
patients can be linked to the reduction in leukemic cell
burden. Treatment with imatinib mesylate (Gleeved,
Novartis) results in a high frequency of complete
cytogenetic response, which can be further stratified
using quantitative reverse-transcriptase polymerase
chain reaction (qRT-PCR). We have serially monitored
peripheral blood and bone marrow BCR-ABL transcripts
using qRT-PCR in CML patients commencing imatinib
therapy.
In keeping with our commitment to
provide state-of-the-art rapid testing, we have recently
validated Cepheid’s BCR-ABL* quantitative assay for
patients with CML. Unlike existing method, which uses
G6PDH as the internal standard, the new assay uses
internal copies of ABL. In our validation studies,
quantitative comparisons showed no significant
differences between using G6PDH or ABL as the reference
gene for this assay.
In keeping with NCCN guidelines and monitoring for BCR/ABL
transcripts, the system delivers an automated, highly
accurate nested real-time PCR assay for rapid,
standardized test reporting in about 2 hours. Unlike
other open systems, the GeneXpert® System is the only
closed instrument platform to combine sample preparation
with real time PCR amplification and detection functions
for fully integrated and automated nucleic acid
analysis. The system purifies, concentrates, detects,
and identifies targeted nucleic acid sequences,
delivering answers from unprocessed samples in about 2
hours.
Contact the laboratory for more
information about this assay.
Irinotecan
Irinotecan (CAMPTOSAR (irinotecan HCl), Pfizer) is a
chemotherapy agent used to treat metastatic colorectal
cancer. CAMPTOSAR is used to treat colon cancer that has
spread to other parts of the body. It is often taken
with 2 other cancer drugs. They are called 5-FU
(fluorouracil) and LV (leucovorin). Combinations
including CAMPTOSAR have been shown to significantly
extend survival for patients with colorectal cancer.
Side effects from taking irinotecan may cause both
"early" and "late" diarrhea. The early form happens
within 24 hours of taking your chemo. It is often mild
and goes away soon. The late form happens more than 24
hours after taking chemo. It can be very serious.
Irinotecan treatment may lower the number of white blood
cells in the body. This is called neutropenia. It means
that you are more likely to get an infection. Diarrhea
and neutropenia may cause severe adverse effects in some
patients. Some patients carry alterations in
the gene responsible for metabolizing irinotecan.
Polymorphisms in this gene, UGT1A1, prevent the
breakdown of the toxic byproduct of irinotecan,
resulting in the associated toxicity of diarrhea and
neutropenia. Most individuals have 2 copies of the same
gene (UGT1A1* 28). Some individuals, however, carry
polymorphisms which can now be identified with genetic
testing. Patients with colorectal cancer can now be
screened for polymorphisms in UGT1A1 before receiving
irinotecan therapy to help identify patients at risk for
adverse effects from the drug.
Testing for
UGT1A1 polymorphisms is now available for patient
identification.
Contact the laboratory for more
information.
Pathology
Customer Service
888-252-3902
Correspondence Shipping Address
LSUHSC
Department of Pathology
1501 Kings Hwy
Shreveport, LA 71130
Specimen Shipping Address
LSUHSC
Pathology
Outreach Services
Attn: Angie Grantham
1541 Kings Hwy
Shreveport, LA 71130 |
|
What is the cost? Cost of testing can be
determined prior to service, if needed. Medical
testing costs are extrapolated based on Current
Procedural Terminology (CPT) codes and established
pricing. Testing costs may vary by individual test
versus testing panel and by patient billing versus
client billing.
What are the hours of operation? The Molecular Pathology
Laboratory at LSUHSC-S operates 24 hours/day 7
days/week. As part of the clinical laboratory, we
have trained staff available and on call throughout the
week.
What information should come with the specimen? A
completed requisition should accompany the specimen and
information including name, date of birth, requesting
physician, insurance provider (if patient-billing versus
client billing) . Contact information for the
referring laboratory/physician is also important.
What types of specimens do you need? All specimens
are accepted. Specimen types vary depending upon
the ordered test. Frequently, specimens may be
shared between varying tests, if a limited specimen
volume is obtained.
What anticoagulants are appropriate for PB & BM
specimens? For conventional cytogenetic studies, sodium
heparin (green top) is preferred. Molecular
genetic analyses generally require a purple top (EDTA)
collection tube. Other collection tubes and
specimen types may be acceptable, depending upon the
test requested. Contact the laboratory for
questions.
If we deliver it, where do we bring it? Deliver all
specimens to the LSUHSC-S Clinical Laboratory receiving
area, 2nd floor LSUHSC-S Hospital. The Clinical
Laboratory office is staffed 24/7.
How
long does it take to receive test results? Testing time
varies by test. Please refer to the estimated
testing time table for a reference. Testing may be
expedited based upon clinical need.
How can
I receive a copy of my test results? Completed
test results are faxed and a hard copy mailed to the
requesting physician. Alternate arrangements can
be made if needed.
Can I
see my test results online? Eventually...we will have a
secure method of client access to their requested tests.
What
is the turn around time? Testing time varies by
test. Please refer to the estimated testing time
table for a reference. Testing may be expedited
based upon clinical need.
Molecular assays have now become essential to the
pathologist and clinician alike in diagnosing and
managing disease. This article highlights the
techniques and molecular targets no longer ancillary
to basic research. Ripe for discussion are the
likely future impact of genetics on clinical care,
the potential models for service provision, and the
broader ethical, legal, and social issues related to
the use of genetic information for non-medical
purposes. Molecular methods are forecasted to
increase in assisting in the diagnosis of human
diseases. The author's mission is to embrace this
discipline and use these technologies in clinical
practice.
|
|
1. |
Molecular Pathology—Translating Research
into Clinical Practice: An Expanding
Frontier in Surgical Oncology
Surgical Oncology Clinics of North
America, Volume 17, Issue 2, April 2008,
Pages 303-321
Mary Lowery Nordberg |
|
|
2. |
Comparative gene expression analysis of a
chronic myelogenous leukemia cell line
resistant to cyclophosphamide using
oligonucleotide arrays and response to
tyrosine kinase inhibitors
Leukemia Research, Volume 31, Issue 11,
November 2007, Pages 1511-1520
Fei Bao, Paula Polk, Mary L. Nordberg, Diana
M. Veillon, Amanda Sun, Michael Deininger,
David Murray, Borje S. Andersson, Reinhold
Munker |
|
|
3. |
Iron chelators reduce chromosomal breaks in
ataxia-telangiectasia cells
DNA Repair, Volume 5, Issue 11, 8
November 2006, Pages 1327-1336
Rodney E. Shackelford, Yumei Fu, Ryan P.
Manuszak, Torrie C. Brooks, Adrian P.
Sequeira, Suming Wang, Mary Lowery-Nordberg,
Anping Chen |
|
|
4. |
Increased transferrin receptor expression
following 11q23 deletion as a mechanism of
malignant progression in chronic lymphocytic
leukemia
Medical Hypotheses, Volume 66, Issue 3,
2006, Pages 509-512
Rodney E. Shackelford, Ami R. Bhalodia,
James D. Cotelingam, Diana M. Veillon, Mary
Lowery-Nordberg |
Congratulations to Scott Crawford. He
participated in the Biomedical Research Foundation
program. Scott studied how genetic typing
could be used to target treatment for colorectal
cancer patients. He researched genetic
mutation and discovered the mutation occurred in
about 20% of the population studied at Feist-Weiller
Cancer Center.
Scott is competing for tuition grants, internships,
and a $50,000 college scholarship. Scott plans to
attend Baylor University or Centenary College and
major in biochemistry. We'll keep you posted
on the results soon.
|
